Medivir appoints Vice President, Research & Development Projects

Medivir appoints Vice President, Research & Development Projects

Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical
company focused on infectious diseases, is pleased to announce the
appointment of Charlotte Edenius to the new position of Vice President,
Research & Development Projects, effective 1 November 2010. This newly
created position, with responsibility for Medivir's project portfolio,
marks another step in the direction of strategically enhancing Medivir's
R&D organisation, and accordingly, Charlotte will become a member of the
company's management. 

Charlotte holds a medical degree and has a Ph.D. from the Karolinska
Institute. She joins Medivir from a position as Senior Vice President
and Chief Scientific Officer of Swedish pharmaceutical company Orexo AB.
Charlotte's previous positions also include being Vice President and
Chief Scientific Officer of Biolipox AB in 2001-2007 and various
executive positions in Experimental Medicine, Clinical R&D AstraZeneca,
at Södertälje, Sweden in 1995-2001 

“I'm very pleased to bring Charlotte Edenius into Medivir in this
position as Vice President, Research & Development Projects where she
will bring key competence to our projects. Her very extensive and
in-depth knowledge of the life sciences sector, from the research side,
preclinical and clinical development, will also reinforce our strategic
endeavor to become a profitable medium-sized company within a five-year
period, with high growth and a focus on infectious diseases,” commented
Bertil Samuelsson, CSO, Research & Development. 

For more information, please contact
Rein Piir, CFO and a VP, IR, +46 (0)70 853 7292. 

About Medivir
Medivir is a research-based specialty pharmaceutical company focused on
the development of high-value treatments for infectious diseases.
Medivir has world-class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product, an innovative treatment for cold
sores. 

Xerese™/Xerclear® is a treatment for cold sores, which has been approved
in both the US and Europe. It is partnered with GSK to be sold OTC in
Europe and Russia and by prescription sold by Meda in North America.
Medivir has retained the Rx rights for Xerclear® in Sweden and
Finland.  

Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase
2b clinical development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals. 

For more information about Medivir, please visit the Company's website:
www.medivir.se (http://www.medivir.se/)